Claire Falandry

机构：Lyon 1 Université, Inserm, Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Hôpital Lyon Sud, Laboratoire de recherche en cardiovasculaire, métabolisme, diabétologie et nutrition, Institut National des Sciences Appliquées de Lyon · ORCID：0000-0001-7267-4723

发表论文 212 篇 · 总被引 5641 次 · h-index 33

代表论文

ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease (2024 · Annals of Oncology · 被引 328)
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial (2023 · Journal of Clinical Oncology · 被引 116)
First-line systemic treatment with palbociclib in women aged ≥70 years presenting with hormone receptor-positive advanced breast cancer: Results from the PALOMAGE program. (2023 · Journal of Clinical Oncology · 被引 23)
Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial (2025 · The Lancet · 被引 16)
Enhancing collaboration between geriatricians, oncologists, and pharmacists to optimize medication therapy in older adults with cancer: A position paper from SOFOG-SFPO (2023 · Critical Reviews in Oncology/Hematology · 被引 16)
Ovarian cancer in the older patient: where are we now? What to do next? (2023 · Therapeutic Advances in Medical Oncology · 被引 15)